Estrogen Receptor Alpha Mutations, Truncations, Heterodimers, and Therapies.

Abstract excerpt

Annual breast cancer (BCa) deaths have declined since its apex in 1989 concomitant with widespread adoption of hormone therapies that target estrogen receptor alpha (ERα), the prominent nuclear receptor expressed in ∼80% of BCa. However, up to ∼50% of patients who are ER+ with high-risk disease experience post endocrine therapy relapse and metastasis to distant organs. The vast majority of BCa mortality occurs in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents, Hormonal
• Share to Breast Neoplasms
• Share to Estrogen Receptor alpha